Analyst Price Target is $95.00
▲ +10.86% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Reata Pharmaceuticals in the last 3 months. The average price target is $95.00, with a high forecast of $121.00 and a low forecast of $67.00. The average price target represents a 10.86% upside from the last price of $85.69.
Current Consensus is
The current consensus among 6 contributing investment analysts is to buy stock in Reata Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX.